Dr. Zaknoen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7471 Circulo Sequoia
Carlsbad, CA 92009Phone+1 858-349-4300
Education & Training
- University of MinnesotaFellowship, Hematology and Medical Oncology, 1987 - 1990
- University of MinnesotaResidency, Internal Medicine, 1984 - 1987
- Indiana University School of MedicineClass of 1984
- Valparaiso UniversityB.S., Chemistry & Biology
Awards, Honors, & Recognition
- Graduated Summa Cum Laude Indiana University School of Medicine, 1984
- Graduated With Distinction Valparaiso University
Clinical Trials
- Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients Start of enrollment: 2007 Oct 01
- APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202) Start of enrollment: 2008 Apr 01
Publications & Presentations
PubMed
- 26 citationsRandomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in ...Martin J. Edelman, Ming Tan, Mary J. Fidler, Rachel E. Sanborn, Greg Otterson
Journal of Clinical Oncology. 2015-01-10 - 80 citationsPhase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.Edward S. Kim, Merrill S. Kies, Frank V. Fossella, Bonnie S. Glisson, Sara Zaknoen
Cancer. 2005-08-01 - 728 citationsA phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseW. K. A. Yung, Robert E. Albright, Jeffrey J. Olson, R Fredericks, Karen Fink
British Journal of Cancer. 2000-09-01
Press Mentions
- aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate UpdateAugust 10th, 2021
- aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara ZaknoenJune 4th, 2021
- aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara ZaknoenMay 25th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: